CN106616995A - 一种健脑口服液及其生产方法 - Google Patents
一种健脑口服液及其生产方法 Download PDFInfo
- Publication number
- CN106616995A CN106616995A CN201611224641.0A CN201611224641A CN106616995A CN 106616995 A CN106616995 A CN 106616995A CN 201611224641 A CN201611224641 A CN 201611224641A CN 106616995 A CN106616995 A CN 106616995A
- Authority
- CN
- China
- Prior art keywords
- brain
- oral liquid
- production method
- liquid production
- brain boosting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 238000005728 strengthening Methods 0.000 title abstract description 5
- 210000004556 brain Anatomy 0.000 claims abstract description 42
- 235000020234 walnut Nutrition 0.000 claims abstract description 18
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 14
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 10
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- 229940067606 lecithin Drugs 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 239000000084 colloidal system Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 241001494479 Pecora Species 0.000 claims description 13
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 8
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 108010084311 Novozyme 435 Proteins 0.000 claims description 5
- 241000235342 Saccharomycetes Species 0.000 claims description 5
- 230000007065 protein hydrolysis Effects 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 240000007049 Juglans regia Species 0.000 claims 1
- 241000758789 Juglans Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000796 flavoring agent Substances 0.000 abstract description 4
- 235000019634 flavors Nutrition 0.000 abstract description 4
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 241000283707 Capra Species 0.000 abstract 2
- 238000009924 canning Methods 0.000 abstract 1
- 235000013681 dietary sucrose Nutrition 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 5
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000002381 Brain Hypoxia Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001482588 Naemorhedus goral Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- XRCRJFOGPCJKPF-UHFFFAOYSA-N 2-butylbenzene-1,4-diol Chemical compound CCCCC1=CC(O)=CC=C1O XRCRJFOGPCJKPF-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101000985497 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) 3-hexulose-6-phosphate synthase 1 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFXSFVVPCLGHAU-UHFFFAOYSA-N benzene;phenol Chemical compound C1=CC=CC=C1.OC1=CC=CC=C1.OC1=CC=CC=C1 RFXSFVVPCLGHAU-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- -1 carrotene Chemical compound 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种健脑口服液及其生产方法。它是将青山羊脑和核桃仁预处理,按一定比例混合后经胶体磨、匀浆、脂肪水解、蛋白质水解,加入卵磷脂和蔗糖接种复合菌混合发酵,过滤后加入芝麻素和VE等灌装为成品,该产品不仅具有良好的健脑效果,还营养丰富、风味独特。
Description
技术领域
本发明涉及一种健脑口服液及其生产方法,属于食品技术领域。
背景技术
我国现有老人2亿以上,帕金森、老年痴呆、小脑萎缩及脑出血脑梗塞等脑疾病呈高发趋势。脑活素易透过血脑屏障直接作用于神经细胞的核酸代谢和蛋白质合成,并影响其呼吸链,具有激活、改善脑内神经递质和酶的活性,增加脑组织对葡萄糖的利用,改善脑细胞缺氧状态,对缺氧的脑细胞有保护作用,可补气养阳、滋肾健脑、益智安神,用于神经衰弱,脑动脉硬化引起的体倦头晕、中风、半身不遂、高血压性脑出血后的脑血肿、脑血栓,失眠多梦,记忆力减退等属于心肝不足,气阳两虚患者。但国外进口的脑活素价格昂贵,国内还处于实验阶段,还没有规模化生产。
青山羊(学名:斑羚Naemorhedusgoral)属偶蹄目斑羚属的一种高山动物。经常置身于孤峰悬崖之上。善于跳跃和攀登,能在悬崖绝壁和深山幽谷之间奔走,也能纵身跳下10m余深的深涧而安然。广布在中国的山东、东北、华北、西北、华南及西南诸省区。青山羊繁殖能力强,成熟母羊年产2次,每次5只左右,能提供较多的脑源;其活波好动,体重娇小,品质优良,是生产脑活素的理想原料。羊脑味甘;性温,每100克约含水分76.3克,蛋白质11.3克,脂肪10.7克,碳水化合物0.1克,钙61毫克,磷356毫克,锌1.24毫克,硫胺素0.17毫克,核黄素0.27毫克,尼克酸3.5毫克。主要功效:补虚健脑、润肤。
核桃仁具有良好的健脑作用。每100克核桃中,含脂肪50~64克,核桃中的脂肪71%为亚油酸,12%为亚麻酸,蛋白质为15~20克,蛋白质亦为优质蛋白,核桃中脂肪和蛋白是大脑最好的营养物质。糖类为10克,以及含有钙、磷、铁、胡萝卜素、核黄素(维生素B2)、维生素B6、维生素E、胡桃叶醌、磷脂、鞣质等营养物质。所含磷脂有补脑作用,是神经细胞新陈代谢的基本物质,故核桃仁称为天然脑黄金。同时核桃仁中所含的α-亚麻酸可在人体内转化成DHA、EPA等。
本发明利用青山羊大脑和核桃仁复配,克服青山羊脑缺乏,难以工业化生产等问题。
发明内容
针对上述问题,本发明提供了一种健脑口服液及其生产方法。本发明首先将青山羊脑和核桃仁预处理,按一定比例混合后经胶体磨、匀浆、脂肪水解、蛋白质水解、混合发酵、超滤等灌装为成品,该产品不仅具有良好的健脑效果,还营养全面、风味独特。
本发明的技术方案是:一种健脑口服液生产方法,其特征是,包括以下步骤:
1)预处理
将去杂后的青山羊脑和去薄皮后的核桃仁按质量比2~4:6~8混合;然后经胶体磨成胶体状后再采用匀浆机匀浆;
2)脂肪水解
然后混合物于pH 7.0-8.0,温度40~50℃下,加入脂肪酶Novozym435酶解,得水解液;
3)蛋白质水解
水解液于pH 8.0-9.0,温度40~50℃下加入胰蛋白酶解;
4)混合发酵
然后于pH为2.0-4.0下,加入其质量1.5~2.5%的蔗糖和1.5~2.5%的卵磷脂,无菌接入乳酸菌、双岐杆菌和酵母菌的复合菌进行混合发酵;
5)过滤、调配
发酵液经过板框过滤后超滤;超滤液加入0.01~0.5%芝麻素和0.1~0.5%的VE,搅拌均匀后灌装。
优选的,所述步骤2)和步骤3)先加热至微沸后再降温至40~50℃下酶解。
优选的,所述步骤3)的脂肪水解为:用NaOH溶液调pH为7.0~8.0,加热微沸后冷却至40~50℃,按1.5~2.5%的质量比加入脂肪酶Novozym435酶解2~5小时,得水解液。
优选的,所述步骤4)的蛋白质水解为:用NaOH溶液调pH为8.0~9.0,加热微沸后冷却至40~50℃,按1.5~2.5%的质量比加入胰蛋白酶酶解3~8小时。
优选的,所述步骤4)的混合发酵为:用柠檬酸调pH为2.5~3.0,加入其质量1.5~2.5%蔗糖和1.5~2.5%卵磷脂,无菌接种乳酸菌15~25毫升/升、双歧杆菌10~20毫升/升和酵母菌10~20毫升/升,35~40℃混合发酵10~15小时。上述发酵中采用香油消泡。
所述步骤5)如果需要长期保存(普通保存3个月以上),需要另外加入特丁基对苯二酚(TBHQ),其保质期可达到18个月以上。所述步骤采用80目板框过滤。
本发明生产的健脑口服液的总N≥5mg/ml,小肽≥30mg/ml,游离氨基酸≥30mg/ml,符合中华人民共和国共和国卫生部WS-198(X-171)-97(1)要求。
本发明的有益效果是:
(1)本发明以青山羊脑和核桃仁为主要原料,产品中富含多种氨基酸、磷脂、尼克酸、DHA,含有多种维生素(尤其是维生素B、C和E)和矿物质,并富含多种脑细胞增殖、生长、发育以及代谢所需的生长因子和调节因子,这些对于维持大脑的基本功能,改善脑缺氧、神经衰弱和失眠健忘的状况具有良好的疗效。
(2)本产品含有乳酸菌、双歧杆菌和酵母菌等益生菌,改善肠胃生态环境,同时经过酶解、发酵和过滤,蛋白质、脂肪和多糖等大分子物质转化为小肽、氨基酸、DHA和单糖等,这些小分子的营养物质容易在肠道吸收,转运到脑部,给脑细胞提供足够的营养物质,并增强脑活力,提高脑神经功能。
(3)本发明经过天然酶解,添加芝麻素和VE等,具有醇香风味;同时可抗氧化,延长产品的保质期。
(4)本发明采取动植物原料结合,即解决了羊脑原料不足的问题,又使营养成分相互补充,为脑部提供全面的营养物质,产品质量更佳、保健效果更好。
具体实施方式
1.预处理
(1)青山羊脑预处理:取青山羊脑,用手术刀、剪刀和镊子等挑出血管、神经和筋隔膜等杂质,用无菌纯净水洗涤,将羊脑切成小块;
(2)核桃仁预处理:将核桃仁在水中浸泡3-5小时,然后脱皮,用无菌纯净水洗涤;
2.粉碎
按照羊脑和核桃仁质量比3:7的比例混合,然后经胶体磨粉碎,粉碎至平均粒度≤50μm的胶体状浆料;然后泵入匀浆机匀浆,转速600转/分,时间10分钟;
3.脂肪水解
泵入反应罐中,用10mol/L的NaOH溶液调pH为7.4,加热微沸后冷却至45℃,按2%的质量比加入脂肪酶Novozym435酶解3.5小时,得水解液;
4.蛋白质水解
水解液泵入反应罐,用10mol/LNaOH调pH为8.0-9.0,加热微沸后冷却至45℃,按2%的质量比加入胰蛋白酶酶解5-6小时;
5.混合发酵
水解液泵入发酵罐,用10mol/L柠檬酸调pH为2.5-3.0,加入其质量2%蔗糖和2%卵磷脂,无菌接种乳酸菌20毫升/升、双歧杆菌15毫升/升和酵母菌15毫升/升,37℃混合发酵12小时,加1‰香油消泡;
按活菌数计乳酸菌、双歧杆菌和酵母菌的含量均要求为≥1亿cfu/ml。
6.过滤、调配
80目板框过滤,滤液泵入HPS-1超滤装置超滤;超滤液泵入搅拌罐,添加0.02%特丁基对苯二酚(TBHQ)、0.1%芝麻素和0.1%的VE,搅拌均匀。
7.灌装
然后泵入灌装机,在百万级净化室内罐装,(棕色瓶、盖等均经无菌纯净水洗涤、灭菌、干燥),每瓶5-10ml。检验、合格产品包装入库。
服用方法:每日2-3次,每次5-10ml,适用于脑缺氧、神经衰弱、失眠健忘等的老年人服用。坚持服用3个月,效果明显。
本实施例生产的健脑生物菌剂含有益生菌总量0.75亿cfu/ml;总N5.23mg/ml,小肽36.9mg/ml,游离氨基酸37.1mg/ml,其中赖氨酸2.61mg/100ml、色氨酸0.51mg/100ml、苯丙氨酸2.09mg/100ml、甲硫氨酸1.28mg/100ml、苏氨酸1.83mg/100ml、异亮氨酸1.96mg/100ml、亮氨酸3.51mg/100ml、缬氨酸2.35mg/100ml,符合中华人民共和国共和国卫生部WS-198(X-171)-97(1)要求。
毒理试验:经小鼠一次经口给予该口服液40ml/kg,安全性好,无不良反应;皮肤刺激强度评价标准,积分<0.5无刺激性;兔一次眼刺激试验平均分为5分,表明该口服液为轻度刺激性物质。
本产品富含多种脑细胞增殖、生长、发育以及代谢所需的生长因子和调节因子,经小白鼠试验,对脑缺氧效果显著。
本产品含有乳酸菌、双歧杆菌和酵母菌等益生菌,改善肠胃生态环境,同时经过酶解、发酵和过滤,蛋白质、脂肪和多糖等大分子物质转化为小肽、氨基酸、DHA和单糖,经小白鼠试验,对肠胃消化吸收效果显著。
本产品经过天然酶解,添加TBHQ、芝麻素和VE等,具有醇香风味;同时可抗氧化,延长产品的保质期。
实施例2
将羊脑和核桃仁质量比2:8的比例混合,其余同实施例1。
实施例3
将羊脑和核桃仁质量比4:6的比例混合,其余同实施例1。
实施例4
不添加0.02%特丁基对苯二酚(TBHQ),添加0.2%芝麻素和0.3%的VE其余同实施例1,所得产品要求在3个月内服用。
实施例5
不添加0.02%特丁基对苯二酚(TBHQ),添加0.3%芝麻素和0.25%的VE其余同实施例1,所得产品要求在3个月内服用。
实施例6
添加1.8%蔗糖和2.2%卵磷脂,其余同实施例1。
实施例7
添加2.3%蔗糖和1.8%卵磷脂,其余同实施例1。
实施例2-7生产的健脑口服液的总N≥5mg/ml,小肽≥30mg/ml,游离氨基酸≥30mg/ml,符合中华人民共和国共和国卫生部WS-198(X-171)-97(1)要求。
Claims (9)
1.一种健脑口服液生产方法,其特征是,包括以下步骤:
1)预处理
将去杂后的青山羊脑和去薄皮后的核桃仁按质量比2~4:6~8混合;然后经胶体磨成胶体状后再采用匀浆机匀浆;
2)脂肪水解
然后混合物于pH 7.0-8.0,温度40~50℃下,加入脂肪酶Novozym435酶解,得水解液;
3)蛋白质水解
水解液于pH 8.0-9.0,温度40~50℃下加入胰蛋白酶解;
4)混合发酵
然后于pH为2.0-4.0下,加入其质量1.5~2.5%的蔗糖和1.5~2.5%的卵磷脂,无菌接入乳酸菌、双岐杆菌和酵母菌的复合菌进行混合发酵;
5)过滤、调配
发酵液经过板框过滤后超滤;超滤液加入0.01~0.5%芝麻素和0.1~0.5%的VE,搅拌均匀后灌装。
2.如权利要求1所述的一种健脑口服液生产方法,其特征是,所述步骤2)和步骤3)先加热至微沸后再降温至40~50℃下酶解。
3.如权利要求2所述的一种健脑口服液生产方法,其特征是,所述步骤3)的脂肪水解为:用NaOH溶液调pH为7.0~8.0,加热微沸后冷却至40~50℃,按1.5~2.5%的质量比加入脂肪酶Novozym435酶解2~5小时,得水解液。
4.如权利要求2所述的一种健脑口服液生产方法,其特征是,所述步骤4)的蛋白质水解为:用NaOH溶液调pH为8.0~9.0,加热微沸后冷却至40~50℃,按1.5~2.5%的质量比加入胰蛋白酶酶解3~8小时。
5.如权利要求1所述的一种健脑口服液生产方法,其特征是,所述步骤4)的混合发酵为:用柠檬酸调pH为2.5~3.0,加入其质量1.5~2.5%蔗糖和1.5~2.5%卵磷脂,无菌接种乳酸菌15~20毫升/升、双歧杆菌10~20毫升/升和酵母菌10~20毫升/升,35~40℃混合发酵10~15小时。
6.如权利要求1所述的一种健脑口服液生产方法,其特征是,所述步骤4)的混合发酵中采用香油消泡。
7.如权利要求1所述的一种健脑口服液生产方法,其特征是,所述步骤5)如果需要长期保存,需要另外加入特丁基对苯二酚。
8.如权利要求1所述的一种健脑口服液生产方法,其特征是,所述步骤5)采用80目板框过滤。
9.权利要求1-8中任意一项所述的方法生产的健脑口服液,其特征是,其总N≥5mg/ml,小肽≥30mg/ml,游离氨基酸≥30mg/ml。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611224641.0A CN106616995A (zh) | 2016-12-27 | 2016-12-27 | 一种健脑口服液及其生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611224641.0A CN106616995A (zh) | 2016-12-27 | 2016-12-27 | 一种健脑口服液及其生产方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106616995A true CN106616995A (zh) | 2017-05-10 |
Family
ID=58832485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611224641.0A Pending CN106616995A (zh) | 2016-12-27 | 2016-12-27 | 一种健脑口服液及其生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106616995A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329071A (zh) * | 2020-03-13 | 2020-06-26 | 江西康宝医药生物科技有限公司 | 一种脑多肽的制备工艺 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121732A (zh) * | 1993-04-26 | 1996-05-01 | 诺沃挪第克公司 | 水解蛋白质的方法 |
| CN1425443A (zh) * | 2002-12-26 | 2003-06-25 | 商宇 | 一种健脑口服液及其制备方法 |
| CN103596447A (zh) * | 2011-05-03 | 2014-02-19 | 雀巢产品技术援助有限公司 | 蛋白底物的水解物及其制备方法 |
| CN104905208A (zh) * | 2015-05-20 | 2015-09-16 | 安徽麦德发食品有限公司 | 一种益肾补脑的禽骨调味品 |
| CN105532898A (zh) * | 2015-12-30 | 2016-05-04 | 林辉 | 一种健脑益智的保健饮料及其制备方法 |
| CN105831290A (zh) * | 2016-04-15 | 2016-08-10 | 合肥珠光粮油贸易有限公司 | 一种有益脑部提升记忆力的米糠油 |
| CN106035750A (zh) * | 2016-06-03 | 2016-10-26 | 凤台县店集粮油工贸有限公司 | 一种有益脑部提升记忆力的米糠油 |
-
2016
- 2016-12-27 CN CN201611224641.0A patent/CN106616995A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121732A (zh) * | 1993-04-26 | 1996-05-01 | 诺沃挪第克公司 | 水解蛋白质的方法 |
| CN1425443A (zh) * | 2002-12-26 | 2003-06-25 | 商宇 | 一种健脑口服液及其制备方法 |
| CN103596447A (zh) * | 2011-05-03 | 2014-02-19 | 雀巢产品技术援助有限公司 | 蛋白底物的水解物及其制备方法 |
| CN104905208A (zh) * | 2015-05-20 | 2015-09-16 | 安徽麦德发食品有限公司 | 一种益肾补脑的禽骨调味品 |
| CN105532898A (zh) * | 2015-12-30 | 2016-05-04 | 林辉 | 一种健脑益智的保健饮料及其制备方法 |
| CN105831290A (zh) * | 2016-04-15 | 2016-08-10 | 合肥珠光粮油贸易有限公司 | 一种有益脑部提升记忆力的米糠油 |
| CN106035750A (zh) * | 2016-06-03 | 2016-10-26 | 凤台县店集粮油工贸有限公司 | 一种有益脑部提升记忆力的米糠油 |
Non-Patent Citations (5)
| Title |
|---|
| "北京查处非法饲养保护动物案", 《大自然》 * |
| 刘伟明等: "山间跃动的精灵――斑羚", 《大自然》 * |
| 弓慧珍: "浅谈痴呆、弱智的预防及治疗", 《父母必读》 * |
| 李志坚: "特种养殖前景概况", 《农业科技与信息》 * |
| 陈正等: "野生动物岂能狂杀滥吃", 《法制与经济》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329071A (zh) * | 2020-03-13 | 2020-06-26 | 江西康宝医药生物科技有限公司 | 一种脑多肽的制备工艺 |
| CN111329071B (zh) * | 2020-03-13 | 2021-08-13 | 江西康宝医药生物科技有限公司 | 一种脑多肽的制备工艺 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070241B (zh) | 一种纯羊乳蛋白婴幼儿配方羊奶粉及其制备方法 | |
| CN102273706A (zh) | 一种牡蛎蛋白饮料的制备方法 | |
| CN102406050A (zh) | 一种核桃小分子多肽及其制备方法 | |
| CN113142437A (zh) | 一种唾液酸复合果蔬汁饮品及其制备方法 | |
| CN103815488B (zh) | 一种西梅饮料的加工方法 | |
| CN102987275B (zh) | 一种高生物效价的大豆低聚糖肽的制备方法 | |
| CN104273613A (zh) | 一种芒果茶菌饮料 | |
| CN107361270A (zh) | 一种红枣酵素饮料的制备方法 | |
| CN101438841A (zh) | 一种西红柿汁保健饮料 | |
| CN101250468A (zh) | 一种螺旋藻葡萄酒及其制备 | |
| CN102805150A (zh) | 一种活菌型莲实玉米酸乳饮料及其制备方法 | |
| CN106616995A (zh) | 一种健脑口服液及其生产方法 | |
| CN102150708A (zh) | 一种怀山药乳乳酸菌植物蛋白饮料及其制法 | |
| CN104962392A (zh) | 洋甘菊提取物的制备方法及加入洋甘菊提取物的保健乳饮料及该乳饮料的制备方法 | |
| CN110547447A (zh) | 一种蜂王浆胶原蛋白水果酵素及其制作方法 | |
| CN107019227A (zh) | 一种香蕉皮膳食纤维、低糖酸奶及其制备方法 | |
| CN109497367A (zh) | 一种蛋清低聚肽果汁饮料及其制备方法 | |
| CN110547448A (zh) | 一种蜂王浆胶原肽水果酵素及其制作方法 | |
| CN106722270A (zh) | 一种青山羊肝口服液及其生产方法 | |
| CN103749718A (zh) | 一种山药奶酪及其制备方法 | |
| CN103070451A (zh) | 一种延长天然蜂蜜保质期的方法 | |
| CN1784997A (zh) | 一种复方微米松花魔芋露减肥降糖酸奶制备方法 | |
| CN1314333C (zh) | 一种微米糖参西天龟鳖铬蜂胶降糖消疲酸奶制备方法 | |
| CN108633998A (zh) | 一种蜂蜜牛奶的制备方法 | |
| CN107637734A (zh) | 一种调理“三高”肽与哈密瓜果汁复配的肽果汁及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |